AOD-9604 in Yad Rambam — Fat Loss Peptide Research Guide
AOD-9604 research guide for Yad Rambam. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
The hunt for AOD-9604 in Yad Rambam inevitably reaches the same conclusion: research peptides are distributed through specialist online vendors, not local retail. This matters because AOD-9604 quality differs enormously across the market — from verified research-grade material to material with significant impurity issues — and the vendor determines everything about the product. Separating genuine research-grade AOD-9604 from the rest of the market depends on three things: an HPLC chromatogram confirming ≥98% purity, mass spec data establishing the correct molecular weight, and a batch-specific endotoxin panel. What follows is a vendor evaluation and quality guide built specifically around AOD-9604, covering everything a Yad Rambam researcher needs to evaluate quality systematically.
What Studies Say About AOD-9604
AOD-9604 belongs to the growth hormone secretagogue (GHS) class, compounds that stimulate pulsatile growth hormone release by acting on the ghrelin receptor (GHSR-1a) or growth hormone releasing hormone (GHRH) receptor. Ipamorelin, GHRP-2, GHRP-6, and Hexarelin all work primarily through GHSR-1a agonism, producing GH pulses with varying specificity profiles. CJC-1295 and Sermorelin work through the GHRH receptor, mimicking the natural hypothalamic signal for GH release. The downstream effect in both cases is increased pulsatile GH secretion and subsequent IGF-1 production in the liver. For researchers in Yad Rambam studying the GH-IGF-1 axis, this mechanistic clarity makes the GHS class a productive experimental tool.
Buying AOD-9604: Quality Markers to Look For
Quality AOD-9604 sourcing begins with a simple filter: does this vendor make batch-matched COAs available before purchase? Vendors who do are operating transparently. When reviewing a AOD-9604 COA, verify: the batch number traces to your order, HPLC purity is ≥98%, mass spec identifies the correct molecular weight, and endotoxin levels are below the threshold for research use. Warning signs in AOD-9604 vendor evaluation: prices more than 30-40% below standard market rates, no information about manufacturing source, no community presence, and COAs that do not include endotoxin results. Keep lyophilised AOD-9604 at −20°C until ready to use; reconstitute only the volume needed for upcoming use and return unused portion to the freezer.
Order AOD-9604 — ships to Yad Rambam
COA-verified · International tracking · Research grade
All use of AOD-9604 in Yad Rambam or anywhere must be research use only — this compound is not approved for clinical human use, and all handling should adhere to research compound handling standards. Storage requirements for AOD-9604: lyophilised powder at freezer temperature, reconstituted solution stored refrigerated at 2-8°C and used within 30 days; reconstitute only with bacteriostatic water. Quality AOD-9604 sourcing directly determines safety outcomes — bacterial endotoxin contamination, incorrect identity, and breakdown products are all safety issues that rigorous vendor evaluation eliminates. PubMed represent the most comprehensive research databases for AOD-9604 research; focus on peer-reviewed publications with documented compound quality over conference abstracts or single case observations.
Frequently Asked Questions
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
